rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Phio Pharmaceuticals Corp.

PHIO · Nasdaq

Health CareBiotechnologyNot moving yet

PHIO stood above a rising 150-day average in 1 of the last 52 weekly readings, and has been out of that trend for the last 51 weeks. It is 20.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 51
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$165K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
23 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 1 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$60KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months12
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Ronald Todd PlottDirectorbought5,000at $1.0429 Sep 2026filed 30 Sep 2026
Ronald Todd PlottDirectorbought5,000at $1.0328 Sep 2026filed 30 Sep 2026
Patricia A. BradfordDirectorbought6,500at $1.0124 Sep 2026filed 25 Sep 2026
Robert J. BittermanChairman, Pres. & CEObought2,000at $1.0322 Sep 2026filed 23 Sep 2026
Patricia A. BradfordDirectorbought12,000at $1.0315 Sep 2026filed 16 Sep 2026
Ronald Todd PlottDirectorbought15,000at $1.1419 Aug 2026filed 20 Aug 2026
Robert J. BittermanChairman, Pres. & CEObought10,000at $1.0618 Aug 2026filed 19 Aug 2026
Robert J. BittermanChairman, Pres. & CEObought10,000at $0.9926 Jun 2026filed 29 Jun 2026
Robert J. BittermanChairman, Pres. & CEObought5,000at $1.0331 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders23+1 on the quarter
New · exited4 · 3
Reported value$650K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCreduced · filed 14 Aug 2026117,755$121K-1,434−1.2%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026114,574$117K-32,680−22.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202694,262$97K+14,409+18.0%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.new · filed 14 Aug 202650,000$51K+50,000
Cetera Investment Advisersadded · filed 12 Aug 202647,500$49K+2,500+5.6%
CITADEL ADVISORS LLCnew · filed 14 Aug 202647,150$48K+47,150
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202638,169$39K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 202627,768$28K+4,010+16.9%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 202621,501$22K-10,994−33.8%
XTX Topco Ltdreduced · filed 14 Aug 202618,475$19K-6,393−25.7%
30 Sep 2024 – 30 Jun 2026
71522Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ronald Todd Plott Company insiderDirector · last 29 Sep 20263 · 0
Lisa Cabott Carson Company insiderChief Financial Officer · last 28 Sep 20260 · 0
Robert J. Bitterman Company insiderChairman, Pres. & CEO · last 28 Sep 202625 · 0
Patricia A. Bradford Company insiderDirector · last 24 Sep 20262 · 0
Curtis Lockshin Company insiderDirector · last 5 Feb 20261 · 0
David H. Deming Company insiderDirector · last 5 Feb 20260 · 0
Jonathan E. Freeman Company insiderDirector · last 5 Feb 20260 · 0
Robert L. Ferrara Company insiderDirector · last 11 Sep 20256 · 0
Robert M. Infarinato Company insiderVP, CFO · last 11 Sep 20240 · 0
Caitlin Kontulis Company insiderSecretary & VP Finance & Admin · last 1 Mar 20240 · 0
Geert Cauwenbergh Company insiderDirector · last 17 Feb 202361 · 0
Gerrit Dispersyn Company insiderPresident & CEO · last 1 Mar 20225 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 2 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$21.0M
Free cash flowFY 2025 · to 31 Dec 2025−$8.0M

Analyst forecasts

No analyst forecasts yet.